For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors...

For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha
Inhibitors Will Decrease Through 2018

Actemra/RoActemra Will Emerge as the Preferred Biological Drug for
TNF-Refractory Patients, According to a New Report from Decision Resources

WALTHAM, Mass., May 18 /PRNewswire/ -- Decision Resources, one of the world's
leading research and advisory firms for pharmaceutical and healthcare issues
finds that, in the treatment of rheumatoid arthritis, the market share for
TNF-alpha inhibitors will decrease to 63 percent through 2018 as a result of
the increasing use of alternative agents to treat the disease. In 2008,
TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's
Humira accounted for 80 percent of rheumatoid arthritis drug sales in the
United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Rheumatoid Arthritis finds that alternative
biologics such as Roche/Chugai's Actemra/RoActemra will take market share away
from the TNF-alpha inhibitors as interviewed rheumatologists indicate they
switch to one of these agents for patients who respond inadequately to two
TNF-alpha inhibitors. Actemra/RoActemra will likely emerge as the preferred
agent for TNF-refractory patients and is forecasted to achieve sales of nearly
$2 billion in 2018.

The report also finds that Centocor Ortho Biotech/Schering-Plough/Mitsubishi
Tanabe/Janssen's Simponi has advantages in its drug delivery and efficacy and
is expected to take significant market share away from Centocor Ortho
Biotech/Schering-Plough/Mitsubishi Tanabe's Remicade. Simponi will also
experience greater uptake than UCB/Otsuka's Cimzia, which has launched for the
indication following its recent approval for rheumatoid arthritis by the Food
and Drug Administration. Additionally, an emerging agent from Pfizer is
expected to impact overall sales of biologics in the market.

"We expect Pfizer's CP-690550, which is in Phase III of development, to steal
patient share from the TNF-alpha inhibitors, in particular, and constrain the
biologics market," said Decision Resources Analyst Joanna Kim, M.Ed. "The
potential of this oral Jak-3 inhibitor was demonstrated by its impressive
efficacy in a recent Phase II clinical study for rheumatoid arthritis."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources, Inc. at
www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Decision Resources, Inc.
Christopher Comfort Elizabeth Marshall
781-296-2597 781-296-2563
ccomfort@dresources.com emarshall@dresources.com

SOURCE Decision Resources

Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com